Flash Finance

Jfl Life Sciences LimitedJFLLIFECorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 10 quarters of data
₹10.85
MCap ₹36 Cr · P/E 5.3
Jfl Life Sciences Limited — Stock analysis & AI research Jfl Life Sciences Limited — Seasonality — best & worst months Jfl Life Sciences Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹11 Cr
Sales · Jun 2026
-4.2% YoY
₹2 Cr
Operating Profit · Jun 2026
+8.5% YoY
18.9%
OPM % · Jun 2026
+13.2% YoY
₹1 Cr
Net Profit · Jun 2026
+48.5% YoY
₹0.34
EPS · Jun 2026
+209.1% YoY

📝 Jfl Life Sciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Jfl Life Sciences Limited reported revenue of ₹11 crore for the quarter ended June 2026 (Q1 FY27), down 4.2% from ₹12 crore in the same quarter last year, and down 82.4% sequentially over the March 2026 quarter.

Net profit rose 48.5% year-on-year to ₹1 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.34.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 18.9%, compared with 16.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Jfl Life Sciences Limited posted revenue of ₹131 crore, a growth of 60.2% over FY25, with a net profit of ₹6 crore (up 53.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹131 crore with a net profit of ₹7 crore.

Valuation snapshot

At the current price of ₹10.85, JFLLIFE has a market capitalisation of ₹36 crore and a trailing P/E of about 5.3.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 16th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 67.47%, public shareholders 32.53% of Jfl Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹36 Cr
Current Price ?
₹10.8
P/E ?
5.29below ind
Industry P/E ?
21.30
P/B ?
0.78
P/S ?
0.27
P/FCF ?
-4.47
Enterprise Value ?
₹58 Cr
EV/EBITDA ?
4.87
PEG ?
0.17
Earnings Yield ?
18.6%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹131 Cr
OPM ?
9.1%
Profit after tax (TTM) ?
₹7 Cr
EPS (TTM) ?
₹2.05
ROCE ?
18.0%
ROE ?
14.7%
ROA ?
6.4%
Growth
Sales — latest qtr ?
₹11 Cr
PAT — latest qtr ?
₹1 Cr
YoY qtr sales growth ?
-4.2%
YoY qtr profit growth ?
48.5%
Sales growth (3y) ?
45%
Sales growth (5y) ?
32%
Profit growth (3y) ?
32%
Profit growth (5y) ?
64%
Financial Health
Debt ?
₹22 Cr
Debt to Equity ?
0.48
Interest Coverage ?
5.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
67.47%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
3.3%
Return 6 months ?
13.0%

🗓️ Quarterly results (10 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 22104021121230276311 -4.2% -82.4%
Operating Profit 2321123342 +8.5% -40.4%
Other Income 0000000000 — -55.5%
Interest 0000000010 +25.7% -70.7%
Depreciation 0000000000 +22.3% +17.8%
Profit Before Tax 1321112321 +4.3% -33.7%
Net Profit 1211012221 +48.5% -32.9%
EPS 0.180.290.220.110.010.110.300.310.250.34 +209.1% +36.0%
OPM % 7.1% 32.1% 6.1% 6.4% 11.8% 16.7% 9.7% 12.5% 5.6% 18.9% +13.2% +237.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹82 Cr ₹131 Cr ₹131 Cr +60.2%
Operating Profit ₹8 Cr ₹12 Cr ₹12 Cr +42.7%
OPM % 10.00% 8.90% 9.06% -11.0%
NPM % 5.10% 4.87% 5.17% -4.5%
Other Income ₹0 Cr ₹0 Cr ₹0 Cr —
Depreciation ₹1 Cr ₹1 Cr ₹1 Cr +7.0%
Interest ₹1 Cr ₹2 Cr ₹2 Cr +97.2%
EBIT ₹7 Cr ₹11 Cr ₹11 Cr +47.6%
PBT ₹6 Cr ₹9 Cr ₹9 Cr +40.1%
Tax — — ₹0 Cr —
Net Profit ₹4 Cr ₹6 Cr ₹7 Cr +53.1%
EPS ₹0.63 ₹0.97 ₹1.20 +54.0%
Material Cost — — ₹7 Cr —
Employee Cost — — ₹0 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 11113333 +0.0%
Reserves 2125613 +116.7%
Borrowings 761122 +100.0%
Other Liabilities 10152239 +77.3%
Total Liabilities 495772106 +47.2%
Fixed Assets 7121215 +25.0%
CWIP 0000 —
Investments 0000 —
Other Assets 42446092 +53.3%
Total Assets 495772106 +47.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -98-4-4 +0.0%
Cash from Investing Activity 1-6-0-4 —
Cash from Financing Activity 8-249 +125.0%
Net Cash Flow -0-001 —
Free Cash Flow -92-4-8 -100.0%
CFO/OP -206%185%-31%-37% -19.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 192203155148 -4.5%
Inventory Days 130145128110 -14.1%
Days Payable 761149893 -5.1%
Cash Conversion Cycle 246233186165 -11.3%
Working Capital Days 221177124103 -16.9%
ROCE % 15%12%16%18% +12.5%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 67.47%67.47%67.47%67.47% +0.0%
Public 32.53%32.53%32.53%32.53% +0.0%
No. of Shareholders 1,008998991971 -2.0%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Jfl Life Sciences Limited's revenue in Q1 FY27?
Jfl Life Sciences Limited reported revenue of ₹11 crore for the quarter ended June 2026 (Q1 FY27), down 4.2% from ₹12 crore in the same quarter last year, and down 82.4% sequentially over the March 2026 quarter.
What was Jfl Life Sciences Limited's net profit in Q1 FY27?
Net profit rose 48.5% year-on-year to ₹1 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.34.
What is JFLLIFE's market capitalisation and P/E ratio?
At the current price of ₹10.85, JFLLIFE has a market capitalisation of ₹36 crore and a trailing P/E of about 5.3.
Who owns Jfl Life Sciences Limited? (shareholding pattern)
As of Mar 2026, promoters held 67.47%, public shareholders 32.53% of Jfl Life Sciences Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI